Company Filing History:
Years Active: 1998
Title: The Innovative Mind of Philippe Delagrance
Introduction
Philippe Delagrance is an accomplished inventor based in Issy-les-Moulineaux, France. He is known for his contributions in the field of medicinal chemistry and has successfully secured a patent that showcases his innovative prowess.
Latest Patents
Philippe holds a patent for tricyclic amide compounds, specifically a compound selected from those of the formula (I): ##STR1##. This innovative compound plays a crucial role in developing a medicinal product aimed at treating mammals afflicted with disorders of the melatoninergic system. His patent reflects a significant advancement in pharmaceutical science.
Career Highlights
Philippe Delagrance is currently associated with Adir et Compagnie, where he applies his expertise to further develop and innovate in the field of medicinal chemistry. His extensive knowledge and research have contributed to the company's growth and reputation in the industry.
Collaborations
Throughout his career, Philippe has worked alongside talented colleagues, including Daniel Lesieur and Patrick Depreux. These collaborations have likely fueled creativity and innovation, leading to significant developments in their respective projects.
Conclusion
Philippe Delagrance's journey as an inventor demonstrates his commitment to advancing science and medicine. His innovative approach and successful patent embody the spirit of ingenuity in the pharmaceutical field. With continued collaborations and research, the impact of his work is sure to resonate in the industry for years to come.
Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.